Recursion Pharmaceuticals, Inc. RXRX Other accounts receivable (net of allowances of $37 in 2026 and $37 in 2025)
Other accounts receivable (net of allowances of $37 in 2026 and $37 in 2025) at other companies
Other financials
Where this comes from
Reported directly by Recursion Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OtherReceivablesNetCurrent.
The official record: Recursion Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Recursion Pharmaceuticals, Inc.'s other accounts receivable (net of allowances of $37 in 2026 and $37 in 2025).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Recursion Pharmaceuticals, Inc.'s other accounts receivable (net of allowances of $37 in 2026 and $37 in 2025)?
- Recursion Pharmaceuticals, Inc. (RXRX) reported other accounts receivable (net of allowances of $37 in 2026 and $37 in 2025) of $13.59M in Q1 2026.
- How has Recursion Pharmaceuticals, Inc.'s other accounts receivable (net of allowances of $37 in 2026 and $37 in 2025) changed year-over-year?
- Recursion Pharmaceuticals, Inc.'s other accounts receivable (net of allowances of $37 in 2026 and $37 in 2025) decreased by 70.5% year-over-year, from $46.12M to $13.59M.